认购事项的所得款项净额估计约为4034万港元(已扣除相关费用及开支)。公司拟将认购事项全部所得款 项净额用于集团一般营运资金及一般业务。 智通财经APP讯，开拓药业-B(09939)发布公告，于2025年8月1日(交易时段前)，公司、童友之及卖方 (KT International Investment Limited)与配售代理订立该协议，据此，(i)卖方同意出售而配售代理同意(作 为卖方的代理)尽最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共2067.3万股股份，相 当于公司于本公告日期的已发行股本约4.62%;及(ii)卖方有条件同意作为委托人按认购价(相当于配售价 每股股份2.08港元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 配售代理有条件同意作为卖方的代理尽最大努力配售2067.3万股股份，相当于经认购事项扩大后的公司 已发行股本约4.42%(假设除发行认购股份外，公司已发行股本自本公告日期起至认购事项完成止并无变 动)。配售价/认购价2.08港元较：股份于2025年7月31日在联交所所报的收市价每股2.56港元折让约 18.75%。 ...

开拓药业-B(09939)发布公告，于2025年8月1日(交易时段前)，公司、童友之及卖方(KT International Investment Limited)与配售代理订立该协议，据此，(i)卖方同意出售而配售代理同意(作为卖方的代理)尽 最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共2067.3万股股份，相当于公司于本公 告日期的已发行股本约4.62%;及(ii)卖方有条件同意作为委托人按认购价(相当于配售价每股股份2.08港 元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 配售代理有条件同意作为卖方的代理尽最大努力配售2067.3万股股份，相当于经认购事项扩大后的公司 已发行股本约4.42%(假设除发行认购股份外，公司已发行股本自本公告日期起至认购事项完成止并无变 动)。配售价/认购价2.08港元较：股份于2025年7月31日在联交所所报的收市价每股2.56港元折让约 18.75%。 认购事项的所得款项净额估计约为4034万港元(已扣除相关费用及开支)。公司拟将认购事项全部所得款 项净额用于集团一般营运资金及一般业务。 ...

Group 1 - The core point of the article is that 开拓药业 (stock code: 9939) announced a financing plan through the placement of existing shares and subscription for new shares, raising approximately HKD 40.34 million [1] - The financing involves the placement of 20,673,000 shares at a price of HKD 2.08 per share, which represents a discount of about 18.8% compared to the last closing price of HKD 2.56 [1] - The shares being placed account for approximately 4.6% of the existing issued share capital and will represent about 4.4% of the enlarged share capital after completion [1] Group 2 - The funds raised will be used for general working capital and business operations of the company [1] - The financing is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed within 14 days from the agreement date or at another time agreed upon by the company, seller, and placement agent [1]

Group 1 - The company, Akeso, announced a placement of 20.7 million shares at a price of HKD 2.08 per share on the Hong Kong Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國或在刊發或派發本公告屬違法的任何其他司 法權區刊發或派發。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。 本公告並不構成或組成在美國或在有關要約屬違法的任何其他司法權區購買或認購證券的 任何要約或招攬的一部分。本公告所述證券未曾亦不會根據經不時修訂1933年美國證券法（「美 國證券法」）或美國任何其他州證券法律登記，而且除非根據美國證券法登記或獲得美國證券 法登記規定的豁免或屬不受美國證券法登記規定約束的交易，否則不得在美國境內發售或出 售。本公司無意根據美國證券法登記本公告所述的任何證券或在美國公開發售證券。 開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） (1) 先舊後新配售現有股份 及 (2) 根據一般 ...

Group 1 - KX-826 1.0% treatment for androgenetic alopecia has completed patient enrollment in Phase III clinical trial with a total of 666 patients [1] - The Phase III trial is designed as a seamless II/III phase study, with the II phase achieving primary endpoints with statistical significance and clinical relevance [1] - The trial is multi-center, randomized, double-blind, and placebo-controlled, assessing the efficacy and safety of KX-826 1.0% and 0.5% in Chinese adult male AGA patients [1] Group 2 - Hong Kong Telecom reported a 4% increase in total revenue to HKD 17.322 billion for the first half of the year [2] - Qingdao Bank's net profit for the first half of the year reached CNY 3.065 billion, a year-on-year increase of 16.05% [2] - Green Tea Group expects a profit of CNY 230 million to 237 million for the first half of the year, representing a year-on-year growth of 32% to 36% [2] Group 3 - Hengrui Medicine received approval for clinical trials of HRS-5041 tablets and other drugs [3] - Hengrui also received approval for clinical trials of SHR-8068 injection, Adalimumab injection, and Bevacizumab injection [3] Group 4 - Lee's Pharmaceutical's Socazolimab has been approved for first-line treatment of extensive-stage small cell lung cancer in mainland China [4] - Yihua Holdings plans to sell a property in Weihai for CNY 64.1077 million [4] - Dexin Services Group intends to acquire 100% equity of Deqing Mogan Mountain Ruijun Real Estate [4]

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

该项关键性临床试验是一项多中心、随机、双盲、赋形剂对照的 II/III 期适应性设计研究，用以评估 KX-826 酊 1.0%和 0.5%外用治疗中国成年男性 AGA 患者的有效性和安全性。该 III 期阶段试验在全国 25 家临床研究中心开展，按照规定的给药剂量进行为期 24 周的治疗和 2 周的安全观察，预计在 2026 年初完成 III 期临床。 格隆汇7月31日丨开拓药业-B(09939.HK)宣布，其自主研发、潜在同类首创的KX-826 酊 1.0%治疗脱发 的关键性临床试验 III 期阶段已完成全部 666 名患者入组。该项关键性临床试验采用 II/III 期操作无缝衔 接设计，II 期阶段已达到主要研究终点，结果具有统计学显着性及临床意义，且有效性和安全性均表现 出色。 ...

Core Viewpoint - The company has completed the enrollment of 666 patients in the pivotal Phase III clinical trial for KX-826 topical solution 1.0% for the treatment of hair loss, which is a potential first-in-class product [1] Group 1: Clinical Trial Details - The pivotal clinical trial employs a seamless II/III phase design, with the Phase II stage achieving its primary endpoint with statistical significance and clinical relevance [1] - The trial is a multi-center, randomized, double-blind, placebo-controlled adaptive design study aimed at evaluating the efficacy and safety of KX-826 topical solutions 1.0% and 0.5% in treating androgenetic alopecia (AGA) in adult males in China [1] - The Phase III trial is being conducted at 25 clinical research centers nationwide, with a treatment duration of 24 weeks followed by a 2-week safety observation period, expected to complete by early 2026 [1] Group 2: Product Development and Market Considerations - Besides KX-826 topical solution and other cosmetic products, the company cannot ensure the successful development and eventual commercialization of other products related to KX-826 [1] - Shareholders and potential investors are advised to act cautiously when trading the company's shares [1]

Core Viewpoint - The company has completed the enrollment of 666 patients in the pivotal Phase III clinical trial for KX-826 topical solution 1.0% for the treatment of hair loss, indicating significant progress in its development pipeline [1] Group 1: Clinical Trial Details - The pivotal clinical trial employs a seamless II/III phase design, with the II phase achieving primary endpoints that are statistically significant and clinically meaningful [1] - The study is a multicenter, randomized, double-blind, placebo-controlled adaptive design aimed at evaluating the efficacy and safety of KX-826 1.0% and 0.5% in treating adult male AGA patients in China [1] - The Phase III trial is being conducted at 25 clinical research centers nationwide, with a treatment duration of 24 weeks followed by a 2-week safety observation period, expected to complete by early 2026 [1] Group 2: Product Development and Market Risks - Apart from KX-826 topical solution and other cosmetic products, the company cannot ensure the successful development and eventual commercialization of other products related to KX-826 [1] - Shareholders and potential investors are advised to act cautiously when trading the company's shares [1]